JP7580815B2 - 骨結合化合物 - Google Patents

骨結合化合物 Download PDF

Info

Publication number
JP7580815B2
JP7580815B2 JP2022504548A JP2022504548A JP7580815B2 JP 7580815 B2 JP7580815 B2 JP 7580815B2 JP 2022504548 A JP2022504548 A JP 2022504548A JP 2022504548 A JP2022504548 A JP 2022504548A JP 7580815 B2 JP7580815 B2 JP 7580815B2
Authority
JP
Japan
Prior art keywords
csa
bone
compound
pharma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022504548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541635A (ja
JP2022541635A5 (https=
Inventor
サベージ，ポール・ビー
シンデラー，アーロン
バルチェフ，ピーター
カンブル，スメド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham Young University
Original Assignee
Brigham Young University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham Young University filed Critical Brigham Young University
Publication of JP2022541635A publication Critical patent/JP2022541635A/ja
Publication of JP2022541635A5 publication Critical patent/JP2022541635A5/ja
Application granted granted Critical
Publication of JP7580815B2 publication Critical patent/JP7580815B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B2017/00831—Material properties
    • A61B2017/00889—Material properties antimicrobial, disinfectant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2022504548A 2019-07-24 2020-07-24 骨結合化合物 Active JP7580815B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878199P 2019-07-24 2019-07-24
US62/878,199 2019-07-24
PCT/US2020/043563 WO2021016583A1 (en) 2019-07-24 2020-07-24 Bone-binding compounds

Publications (3)

Publication Number Publication Date
JP2022541635A JP2022541635A (ja) 2022-09-26
JP2022541635A5 JP2022541635A5 (https=) 2023-02-27
JP7580815B2 true JP7580815B2 (ja) 2024-11-12

Family

ID=74194302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022504548A Active JP7580815B2 (ja) 2019-07-24 2020-07-24 骨結合化合物

Country Status (8)

Country Link
US (1) US20220273673A1 (https=)
EP (1) EP4003201A4 (https=)
JP (1) JP7580815B2 (https=)
KR (1) KR20220041152A (https=)
CN (1) CN114585316A (https=)
AU (1) AU2020319089A1 (https=)
CA (1) CA3145403A1 (https=)
WO (1) WO2021016583A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12215126B2 (en) 2020-05-21 2025-02-04 Brigham Young University Cationic steroidal antimicrobial compounds with endogenous groups
WO2023064802A1 (en) * 2021-10-13 2023-04-20 The Trustees Of Columbia University In The City Of New York Methods for controlling osteocalcin release
US20250073248A1 (en) * 2023-09-05 2025-03-06 Brigham Young University Bioresorbable cationic steroidal antimicrobial compounds with glyceride linkages

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011508757A (ja) 2008-01-03 2011-03-17 ユニベルシテ ドゥ ナント 骨組織を標的としたベクターとしてのヒドロキシ‐ビスホスホン酸誘導体
WO2013029059A1 (en) 2011-08-25 2013-02-28 Brigham Young University Medical devices incorporating ceragenin-containing composites
JP2014514288A (ja) 2011-03-28 2014-06-19 アトランテラ 二機能性ヒドロキシ−ビスホスホン酸誘導体
US20160095932A1 (en) 1998-04-02 2016-04-07 Mbc Pharma, Inc. Bone Targeted Therapeutics and Methods of Making and Using the Same
JP2017514910A (ja) 2014-05-02 2017-06-08 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 骨選択的骨形成オキシステロールビスホスホネート類似体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2303288A4 (en) * 2008-05-22 2015-04-22 Univ Ramot CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESE MEDIUM AND ITS USE IN THE TREATMENT AND CONTROL OF ILLNESSES RELATED TO BONE
US9694019B2 (en) * 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
EP2755661A1 (en) * 2011-09-13 2014-07-23 Brigham Young University Compositions for treating bone diseases and broken bones
CN104147614B (zh) * 2013-05-15 2016-08-24 深圳先进技术研究院 一种阿伦膦酸功能化的聚乙二醇修饰的纳米颗粒及其制备方法
US9931350B2 (en) * 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160095932A1 (en) 1998-04-02 2016-04-07 Mbc Pharma, Inc. Bone Targeted Therapeutics and Methods of Making and Using the Same
JP2011508757A (ja) 2008-01-03 2011-03-17 ユニベルシテ ドゥ ナント 骨組織を標的としたベクターとしてのヒドロキシ‐ビスホスホン酸誘導体
JP2014514288A (ja) 2011-03-28 2014-06-19 アトランテラ 二機能性ヒドロキシ−ビスホスホン酸誘導体
WO2013029059A1 (en) 2011-08-25 2013-02-28 Brigham Young University Medical devices incorporating ceragenin-containing composites
JP2017514910A (ja) 2014-05-02 2017-06-08 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 骨選択的骨形成オキシステロールビスホスホネート類似体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Rebecca MILLS et al.，"CSA-90 Promotes Bone Formation and Mitigates Methicillin-resistant Staphylococcus aureus Infection in a Rat Open Fracture Model"，Clinical Orthopaedics & Related Research，2018年04月26日，Vol. 476, No. 6，p.1311-1323，DOI: 10.1097/01.blo.0000533624.79802.e1
Tom J. HOUGHTON et al.，"Linking Bisphosphonates to the Free Amino Groups in Fluoroquinolones: Preparation of Osteotropic Prodrugs for the Prevention of Osteomyelitis"，Journal of Medicinal Chemistry，2008年10月04日，Vol. 51, No. 21，p.6955-6969，DOI: 10.1021/jm801007z
V HENGST et al.，"Bone targeting potential of bisphosphonate-targeted liposomesPreparation, characterization and hydroxyapatite binding in vitro"，International Journal of Pharmaceutics，2007年03月01日，Vol. 331, No. 2，p.224-227，DOI: 10.1016/j.ijpharm.2006.11.024

Also Published As

Publication number Publication date
KR20220041152A (ko) 2022-03-31
JP2022541635A (ja) 2022-09-26
US20220273673A1 (en) 2022-09-01
CN114585316A (zh) 2022-06-03
AU2020319089A1 (en) 2022-03-03
EP4003201A4 (en) 2023-08-23
WO2021016583A1 (en) 2021-01-28
CA3145403A1 (en) 2021-01-28
EP4003201A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
JP7580815B2 (ja) 骨結合化合物
AU2008258285B2 (en) Wound repair composition and method
WO2013119058A1 (ko) 골 융합 향상 및 항균 효능을 갖는 항생제와 골형성 촉진 물질 방출형 임플란트 또는 스캐폴드 및 그 제조방법
JP7418475B2 (ja) バイオフィルムが関与する細菌感染症を治療するための医薬及びその使用
JP2019030671A (ja) 薬物放出のための化合物及び組成物
Larrañaga-Vera et al. Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models
Nayak et al. Bone-targeted drug delivery systems
US10751351B2 (en) Medicament for treatment of diabetic foot infections
US20040241173A1 (en) Fullerene (C60) vancomycin conjugates as improved antibiotics
CN110114366A (zh) 双膦酸喹诺酮缀合物及其用途
US20230130132A1 (en) Pharmaceutical compositions comprising amphiphilic peptides and methods of use thereof
EA048481B1 (ru) Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой
CA3014541C (en) Medicament for treatment of diabetic foot infections
Wang Targeted Delivery of Dasatinib for Accelerated Bone Fracture Repair
CN102159218A (zh) 用于医学用途的新型几丁低聚物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240716

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240927

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241023

R150 Certificate of patent or registration of utility model

Ref document number: 7580815

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150